[CAS NO. 1446790-62-0] RO9021
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1446790-62-0]
Store
Catalog
SLK-S7286
Brand
Selleck
CAS
1446790-62-0
DESCRIPTION [1446790-62-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 355.44 |
| Molecular Formula | C18H25N7O |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8134 mL | 14.0671 mL | 28.1341 mL |
| 5 mM | 0.5627 mL | 2.8134 mL | 5.6268 mL |
| 10 mM | 0.2813 mL | 1.4067 mL | 2.8134 mL |
| 50 mM | 0.0563 mL | 0.2813 mL | 0.5627 mL |
Description
RO9021 potently inhibits activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.
Targets
| Syk [1] (Cell-free assay) |
| 5.6 nM |
In vitro
RO9021 suppresses BCR signaling in human peripheral blood mononuclear cells (PBMC) and whole blood, FcγR signaling in human monocytes, and FcεR signaling in human mast cells and blocks osteoclastogenesis from mouse bone marrow macrophages in vitro. Toll-like Receptor(TLR) 9 signaling in human Bcells was inhibited by RO9021, resulting in decreased levels of plasmablasts, immunoglobulin (Ig)M and IgG upon B-cell differentiation. RO9021 also potently inhibited type I interferon production by human plasmacytoid dendritic cells (pDC) upon TLR9 activation. This effect is specific to TLR9 as RO9021 did not inhibit TLR4- or JAK-STAT-mediated signaling. RO9021 does not appreciably inhibit the JAK-STAT pathway.
In vivo
Oral administration of RO9021 inhibits arthritis progression in the mCIA model.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.